Sam Altman publicly backed the Trump administration's new artificial intelligence executive order this week, signaling that major AI companies are aligning with tighter federal regulation. The OpenAI CEO met with Trump administration officials and lawmakers to endorse the order, which governs how AI is developed and deployed across the United States. At the same time, Altman's company joined rival Anthropic in urging Congress to strengthen tracking of synthetic DNA sequences, acknowledging that generative AI could accelerate biological weapons development.

Why Is Sam Altman Supporting Stricter AI Regulation?

Altman's public endorsement of the Trump administration's AI executive order reflects a strategic shift in how OpenAI positions itself within Washington's regulatory landscape. The order addresses multiple concerns including safety testing, copyright protections, misinformation prevention, and AI market concentration. By backing the order, Altman is signaling that OpenAI welcomes federal oversight, a move that comes as the company recently restructured into a for-profit benefit corporation and faces increased scrutiny from lawmakers and competitors.

The regulatory environment matters significantly for OpenAI's future. The company's technology powers Microsoft's Copilot product, while competitors like Alphabet's Gemini and Anthropic's Claude vie for market dominance. Pending lawsuits over training data and copyright could be shaped by this federal policy, making Altman's early alignment with the Trump administration a calculated move to influence how those rules ultimately take shape.

What Are OpenAI and Anthropic Asking Congress to Do About DNA Tracking?

Beyond the executive order, OpenAI and Anthropic led a coalition that sent a formal letter to Congress this week proposing concrete measures to prevent misuse of AI in biological weapons development. The two companies are urging lawmakers to implement mandatory federal tracking of synthetic DNA sequences, screen DNA synthesis vendors, and conduct risk assessments of DNA synthesis orders.

This effort acknowledges a real concern: generative AI models can process biological information and accelerate the design of dangerous pathogens. By proposing these safeguards now, OpenAI and Anthropic are attempting to shape regulation before Congress acts unilaterally, a strategy that also positions them as responsible corporate actors rather than obstacles to oversight.

How Regulatory Clarity Shapes AI Investment and Adoption

• Investor Focus: Technology stocks seen as proxies for AI development, including Microsoft and Nvidia, are now being evaluated based on how regulatory changes will affect their growth trajectories and capital spending decisions.
• Chip Demand Impact: The compute demands of advanced AI models continue to fuel chip demand at Nvidia, and tighter rules could shape how quickly AI infrastructure spreads across industries and enterprises.
• Legal Friction Reduction: Regulatory clarity determines how quickly AI adoption proceeds without legal friction, allowing companies to invest in AI infrastructure with greater confidence about compliance requirements.

For investors and technology companies, the stakes are high. Uncertainty about the Trump administration's AI order has kept several provisions closely held, sharpening investor focus on how these rules will ultimately affect major tech firms. The balance between innovation and oversight will determine capital allocation across the sector for years to come.

Altman's move to publicly back the executive order while simultaneously pushing Congress on DNA tracking demonstrates a nuanced strategy: OpenAI is positioning itself as a willing partner in regulation while also shaping the specific rules that will govern its operations. This approach allows the company to influence the regulatory framework rather than simply react to it, a significant advantage as Washington moves toward stricter AI governance.